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Background: Basal-like and triple-negative breast tumours encompass an important clinical subgroup and
biomarkers that can prognostically stratify these patients are required.
Materials and methods: We investigated two breast cancer tissue microarrays for the expression of calpain-1,
calpain-2 and calpastatin using immunohistochemistry. The ﬁrst microarray was comprised of invasive tumours from
1371 unselected patients, and the veriﬁcation microarray was comprised of invasive tumours from 387 oestrogen
receptor (ER)-negative patients.
Results: The calpain system contains a number of proteases and an endogenous inhibitor, calpastatin. Calpain activity
is implicated in important cellular processes including cytoskeletal remodelling, apoptosis and survival. Our results show
that the expression of calpastatin and calpain-1 are signiﬁcantly associated with various clinicopathological criteria
including tumour grade and ER expression. High expression of calpain-2 in basal-like or triple-negative disease was
associated with adverse breast cancer-speciﬁc survival (P = 0.003 and <0.001, respectively) and was veriﬁed in an
independent cohort of patients. Interestingly, those patients with basal-like or triple-negative disease with a low level of
calpain-2 expression had similar breast cancer-speciﬁc survival to non-basal- or receptor- (oestrogen, progesterone or
human epidermal growth factor receptor 2 (HER2)) positive disease.
Conclusions: Expression of the large catalytic subunit of m-calpain (calpain-2) is signiﬁcantly associated with clinical
outcome of patients with triple-negative and basal-like disease.
Key words: basal, breast cancer, calpain, calpastatin, triple negative
introduction
Breast cancer is a heterogeneous disease that displays a
range of phenotypes with different clinical characteristics
including altered clinical outcome, varying prognostic
characteristics and differential response to treatment. The
triple-negative and basal-like subgroups of breast cancer are
of considerable clinical interest as they exhibit an aggressive
phenotype and a higher metastatic potential. Triple-negative
breast cancer lacks expression of both oestrogen receptor
(ER) and progesterone receptor (PgR) and do not
overexpress human epidermal growth factor receptor 2
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(HER2); this subgroup accounts for 10–24% of invasive
breast cancers [1]. Although basal differentiation of breast
cancer was shown in 1971 [2], the molecular classiﬁcation
of distinct classes of breast cancer, including basal-like, was
shown by microarray analysis in 2000 by Perou and
colleagues; the results of which have been veriﬁed in
subsequent studies [3–5]. There is a substantial overlap
between the two groups; however, not all basal-like breast
cancers are triple-negative [6]. There are currently no
speciﬁc therapies for either triple-negative or basal-like
breast cancer. A number of biomarkers have emerged,
which show an association with clinical outcome in basal-
like or triple-negative disease, including solute carrier
organic anion transporter family member 1B1 (OATP2)
and fatty acid-binding protein 7 (FABP7) [7], and forkhead
box protein C1 (FOXC1) [8] in basal-like cancers. In
triple-negative disease, a number of biomarkers are
associated with clinical outcome including p53 [9] and
DNA repair proteins—ERCC4 (XPF), MAP kinase-activated
protein-2 (pMK2), DNA mismatch repair protein MLH1
(MLH1), fanconi anaemia complementation group D2
(FANCD2) [10] and high-molecular weight cytokeratin
(34betaE12) [11]. There is a need to identify additional
prognostic biomarkers to aid stratiﬁcation of breast cancer
patients diagnosed with triple-negative and basal-like
disease, and that could potentially identify novel treatment
regimens.
The calpains are a family of neutral cysteine proteases
that require calcium for their catalytic activity. The
ubiquitously expressed micro (µ) and milli (m) calpains
are named for the concentration of calcium required for
their activation, and are part of a family of at least 15
members [12]. The cellular activity of calpain is, in part,
regulated by their endogenous inhibitor calpastatin. The
calpains function in the controlled proteolysis of a large
number of speciﬁc substrates involved in various cellular
processes such as migration, cell signalling and apoptosis.
The activity and expression of calpains are altered in a
number of tumour types [13]; and in breast cancer, high
calpain-1 expression has been associated with relapse-free
survival of HER2-positive patients treated with
trastuzumab following adjuvant chemotherapy [14]. In
addition, low expression of calpastatin has been associated
with lymphatic vessel invasion in breast cancer [15].
Calpain expression in basal-like and triple-negative
tumours has not been previously described; however, a
relationship exists between calpain-2 and cyclin-E, which
has been associated with basal-like phenotype [16, 17].
Furthermore, recent analysis has established a role for an
extracellular-signal-related kinase (ERK) 1/2 subnet
preferentially activated in basal breast cancer, in which
calpain-2 is implicated [18]. Due to the in vitro
importance attributed to calpain activity and limited but
positive clinical studies previously performed in breast
cancer, the aim of the current study was to investigate the
expression of calpain and calpastatin in a large cohort of
breast cancers with long-term follow-up. This allowed
assessment of protein expression in subgroups such as
triple-negative and basal-like breast cancer.
materials and methods
study patients
This retrospective study was conducted using two independent cohorts of
patients; an initial biomarker discovery cohort consisting of 1371 patients
and a veriﬁcation cohort of 387 ER-negative patients. The discovery cohort
comprises a well-characterised consecutive series of early-stage invasive
breast cancer patients treated at Nottingham University Hospitals, between
1987 and 1998 with long-term follow-up. The median age of the cohort
was 55 years (ranging from 18 to 72) and 62% (850 of 1371) of patients
had stage I disease. Information on clinical history and outcome is
prospectively maintained and patients were assessed in a standardised
manner for clinical history and tumour characteristics (Table 1). Data on a
wide range of biomarkers are available; ER, PgR, HER2 status and p53
expression were available for this cohort and have been described
previously [19]. ER and PgR were positive if staining was above 1%, and
HER2 was positive if staining by immunohistochemistry (IHC) was 3+,
with 2+ conﬁrmed by ﬂuorescence in situ hybridisation. A pragmatic
deﬁnition of basal phenotype, whereby expression of cytokeratin (CK)-5/6
and/or CK-14 above 10% was deﬁned as basal phenotype, irrespective of
ER, PgR or HER2 receptor status, was used for this study [20]. Breast
cancer-speciﬁc survival was deﬁned as the time interval (in months)
between the start of primary surgery and death resultant from breast
cancer. Similarly, relapse-free survival was deﬁned as the time interval (in
months) between the start of primary treatment and date of disease relapse.
Patients were managed under a uniform protocol, where all underwent
mastectomy or wide local excision followed by radiotherapy. Patients
received systemic adjuvant treatment on the basis of Nottingham
prognostic index (NPI), ER and menopausal status. Patients with an NPI
score <3.4 did not receive adjuvant treatment and patients with an NPI
score of 3.4 were candidates for CMF chemotherapy (cyclophosphoamide,
methotrexate and 5-ﬂuorouracil) if they were ER negative or
premenopausal; and hormonal therapy if they were ER positive.
The veriﬁcation cohort used in the current study comprised of patients
with ER-negative tumours, who were independent from those investigated
in the discovery cohort. Patients in this cohort were treated at Nottingham
University Hospitals between 1998 and 2006. The median age of the cohort
was 53 years (ranging from 24 to 71) and 63% (245 of 387) of patients had
stage I disease. As before, clinical history and outcome are prospectively
maintained and patients were assessed in a standardised manner for
clinical history and tumour characteristics (Table 1).
This study is reported in accordance with REMARK criteria [21] and
was approved by Nottingham Research Ethics Committee 2 under the title
‘development of a molecular genetic classiﬁcation of breast cancer’.
Tissue Microarray and IHC
Expression of calpastatin, calpain-1 and calpain-2 was investigated using two
tissue microarrays (TMAs) which were prepared using 0.6-mm cores as
described previously [22]. Freshly cut 4-µm sections of the TMAs were stained
using a streptavidin–biotin method using the primary antibodies; mouse anti-
calpastatin (1 : 20 000), mouse anti-calpain-1 (1 : 5000) and rabbit anti-
calpain-2 (1 : 5000) (all Chemicon, MA, USA, clones PI-11, P-6 and rabbit
polyclonal AB1625, respectively with speciﬁcity conﬁrmed by western
blotting) as previously described [14]. Assessment of staining was conducted
at ×20 magniﬁcation using an immunohistochemicalH-score after scanning
of the slides with a Nanozoomer Digital Pathology Scanner (Hamamatsu
Photonics). Expression of Calpastatin, calpain-1 and calpain-2 was assessed
semi-quantitatively using an immunohistochemical H-score. Staining intensity
was assessed as; none (0), weak (1), medium (2) and strong (3) over the
percentage area of each staining intensity. H-scores were calculated by
multiplying the percentage area by the intensity grade (H-score range 0–300).
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Greater than 30% of cores were double assessed for each protein in each
TMA. Single measure intraclass correlation coefﬁcients between scores for
the discovery TMA were 0.891, 0.886 and 0.860 for calpastatin, calpain-1
and calpain-2, respectively showing excellent concordance between scorers.
statistical analyses
The relationship between categorised protein expression and
clinicopathological variables was assessed using the Pearson χ2 test of
association. Survival curves were plotted according to the Kaplan–Meier
method and signiﬁcance determined using the log-rank test. Multivariate
survival analysis was performed by the Cox proportional hazards regression
model. All differences were deemed statistically signiﬁcant at the level of P
< 0.05. Statistical analysis was performed using SPSS 17.0 software.
Stratiﬁcation cut points were determined using X-Tile software and were
determined before statistical analyses [23]. X-tile is a programme designed
for assessing the relationships between clinical outcome and biomarker
expression capable of cut-point selection.
results
staining location and frequency—discovery cohort
As previously observed calpastatin, calpain-1 and calpain-2
demonstrated cytoplasmic staining with some granularity and
heterogeneity between adjacent tumour cells, varying from
weak to intense staining. Nuclear staining was observed
extremely infrequently for calpastatin (10 cases), calpain-1 (3
cases) and calpain-2 (7 cases), with no overlap on stained cases
between proteins. Calpastatin had a median H-score of 100
and ranged between 0 and 280; calpain-1 had a median value
of 100 and ranged between 0 and 300 and calpain-2 staining
had a median value 70 and ranged between 0 and 240.
Photomicrographs showing representative staining patterns are
shown in Figure 1. Of the tumours analysed 57% (776 of 1371)
were invasive ductal carcinomas of no special type, 16%
(226 of 1371) were tubular mixed, 7% (98 of 1371) were classic
lobular, all other subcategories did not have an individual
frequency above 5% of all observations.
Calpastatin, calpain-1 and calpain-2 H-scores were
dichotomised using X-Tile software into low and high
immunoreactivity and correlated with clinicopathological
Table 1. Clinicopathological variables of the primary cohort of 1371
patients and the veriﬁcation cohort of 387 patients assessed using
immunohistochemistry for markers, calpain-1, calpain-2 and calpastatin
Variable Primary cohort Validation cohort
N (%) N (%)
Age (years)
<40 95 (7) 56 (14)
≥40 1275 (93) 331 (86)
ND 1 0
Size (cm)
<2 686 (50) 184 (50)
≥2 683 (50) 187 (50)
ND 2 16
Stage
I 850 (62) 245 (64)
II 394 (29) 94 (24)
III 125 (9) 45 (12)
ND 2 3
Grade
I 242 (18) 1 (0)
II 456 (33) 40 (10)
III 673 (49) 346 (89)
ND 0 0
Node status
Negative 727 (61) 243 (64)
Positive 458 (39) 138 (36)
ND 186 6
NPI
Good (<3.4) 393 (29) 23 (6)
Intermediate (3.4–5.4) 743 (55) 271 (70)
Poor (>5.4) 225 (17) 91 (24)
ND 10 2
ER
Negative 347 (26) 387 (100)
Positive 983 (74) 0 (0)
ND 41 0
PgR
Negative 548 (42) 313 (98)
Positive 744 (58) 7 (2)
ND 79 67
HER2
Negative 1159 (87) 276 (83)
Positive 175 (13) 58 (17)
ND 37 53
Classiﬁcation
Non-triple negative 1088 (79) 58 (19)
Triple negative 236 (18) 253 (81)
ND 47 76
Basal phenotype
Non-basal 1009 (79) 165 (53)
Basal 270 (21) 149 (47)
ND 92 73
LVI
Negative 748 (67) ND
Positive 361 (33)
ND 262
Continued
Table 1. Continued
Variable Primary cohort Validation cohort
N (%) N (%)
IT-LVI
Negative 969 (87) ND
Positive 139 (13)
ND 263
PT-LVI
Negative 812 (73) ND
Positive 297 (27)
ND 262
ND, not determined; NPI, Nottingham prognostic index; ER, oestrogen
receptor; PgR, progesterone receptor; LVI, lymphatic vessel invasion; IT-
LVI, intra-tumoural LVI; PT-LVI, peri-tumoural LVI.
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criteria. X-tile generated cut points were as follows: calpastatin
had a H-score cut point of 35 with 13% (177 of 1266) of cases
having a low score; calpain-1 had a H-score cut point of 140
with 75% (1024 of 1315) of cases having a low score; calpain-2
had a H-score cut point of 60 with 25% (342 of 1286) of cases
having a low score. A small number of TMA cores were not
assessed due to missing cores or insufﬁcient representative
tumour.
relationship with clinicopathological variables—
discovery cohort
The expression of calpain-1, calpain-2 and calpastatin was
assessed for association with a number of clinicopathological
variables (Table 2). High calpastatin expression was
signiﬁcantly associated with older patients (χ2 = 9.7; 1 df;
P = 0.002), low grade (χ2 = 12.6; 2 df; P = 0.002), low NPI score
(χ2 = 13.3; 2 df; P = 0.001), ER- and PgR-positive tumours
(χ2 = 11.9; 1 df; P = 0.001 and χ2 = 13.1; 1 df; P < 0.001,
respectively), non-basal phenotype (χ2 = 8.7; 1 df; P = 0.003),
tumours <2 cm (χ2 = 5.2; 1 df; P = 0.022) and the absence
of intra-tumoural lymphovascular invasion (χ2 = 6.1; 1 df;
P = 0.014).
High calpain-1 expression was signiﬁcantly associated with
ER- and PgR-positive tumours (χ2 = 10.2; 1 df; P = 0.001 and
χ2 = 7.9; 1 df; P = 0.005, respectively) and low grade tumours
(χ2 = 8.6; 2 df; P = 0.014). Calpain-2 expression was
signiﬁcantly associated with the presence of peri-tumoural
lymphovascular invasion (χ2 = 5.2; 1 df; P = 0.022).
relationship with clinical outcome—discovery
cohort
The expression of calpastatin and calpain-1 were not
signiﬁcantly associated with breast cancer-speciﬁc survival or
relapse-free interval in the total patient cohort. High calpain-2
expression was associated with worse relapse-free survival
(P = 0.043); however, in multivariate Cox regression calpain-2
expression was not an independent indicator of relapse-free
survival (HR = 1.178; 95% CI = 0.914–1.520; P = 0.206). In the
multivariate Cox regression, the potential confounding factors
of patient age, tumour size, stage and grade, node status, NPI,
ER status, PgR status, HER2, basal-like and lymphovascular
invasion were included [with individual Kaplan–Meier
statistics of P < 0.001 for all variables except age (P = 0.001),
ER status (P = 0.007), PgR status (P = 0.001) and basal-like
(P = 0.009)].
The expression of calpastatin and calpain-1 was not
associated with breast cancer speciﬁc- or relapse-free
survival of patients with triple-negative or basal-like
tumours. However, Kaplan–Meier analyses demonstrated
that patients with triple-negative or basal-like tumours had
a signiﬁcantly worse prognosis if they had high expression
of calpain-2 (P = 0.003 and <0.001, respectively; Figure 2).
Furthermore, Kaplan–Meier analyses were performed on
only triple-negative and basal-like subgroups, where
calpain-2 expression remained signiﬁcant (P = 0.043 and
0.025, respectively; Figure 3). If the alternative ‘core basal’
deﬁnition is used to deﬁne the basal phenotype (triple-
negative cases with any expression of CK5/6 and/or
epidermal growth factor receptor (EGFR) [24]), calpain-2
expression remains statistically associated with survival for
patients with core basal tumours (P = 0.050).
Veriﬁcation cohort
To verify the ﬁnding that calpain-2 expression is
signiﬁcantly important in triple-negative and basal-like
disease and could prognostically stratify patients, an
independent patient cohort was investigated.
Clinicopathological criteria of this cohort are shown in
Table 1. Of the 387 ER-negative patients, 65% (253 of 387)
had triple-negative tumours and 39% (149 of 387) had
basal-like tumours. A similar staining pattern was observed
in comparison to the discovery TMA. The cohort had a
median H-score of 135 and ranged between 10 and 280. A
new X-tile cut point was determined for the cohort due to
the complete ER-negative bias of this cohort (H-score of
145). Kaplan–Meier analysis was performed on the patients
with triple-negative and basal-like disease within the cohort,
and high calpain-2 expression was signiﬁcantly associated
with breast cancer-speciﬁc survival in both subgroups
(P = 0.033 and 0.020, respectively; Figure 4).
Figure 1. Representative photomicrographs of high and low levels of
expression. (A) High calpain-1 and (B) low calpain-1 expression. (C) High
calpain-2 and (D) low calpain-2 expression. (E) High calpastatin and
(F) low calpastatin expression. Photomicrographs are at ×10 magniﬁcation
with ×20 magniﬁcation inset box where scale bar shows 50 µm.
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discussion
This study investigated the expression levels of calpastatin,
calpain-1 and calpain-2 in breast cancer using
immunohistochemistry. Calpastatin expression is signiﬁcantly
associated with patient age, tumour size and grade, NPI, ER
and PgR status, triple-negative and basal-like disease and intra-
tumoural lymphatic vessel invasion. Calpain-1 expression was
Table 2. Association between calpastatin, calpain-1 and calpain-2 protein expression and clinicopathological variables
Variable Calpastatin (n = 1266) Calpain-1 (n = 1315) Calpain-2 (n = 1286)
Low High P-value Low High P-value Low High P-value
Age (years)
<40 22 66 0.002 78 14 0.097 25 65 0.796
≥40 154 1023 945 277 317 878
Size (cm)
<2 74 555 0.022 505 148 0.616 172 473 0.929
≥2 103 532 518 142 169 470
Stage
I 106 671 0.624 637 170 0.387 216 574 0.754
II 51 318 288 94 96 277
III 20 98 97 27 30 91
Grade
I 23 197 0.002 175 57 0.014 58 172 0.412
II 45 378 328 114 107 323
III 109 514 521 120 177 449
Node status
Negative 94 571 0.847 522 165 0.500 195 477 0.203
Positive 59 371 331 115 111 324
NPI
Good (<3.4) 30 329 0.001 294 84 0.646 91 279 0.501
Intermediate (3.4–5.4) 111 572 548 160 193 500
Poor (>5.4) 35 179 176 43 55 158
ER
Negative 64 265 0.001 275 52 0.001 83 242 0.667
Positive 106 794 718 232 247 676
PgR
Negative 90 408 <0.001 422 98 0.005 142 368 0.383
Positive 75 623 537 185 180 523
HER2
Negative 149 923 0.726 853 253 0.280 299 783 0.058
Positive 21 142 139 33 35 134
Classiﬁcation
Non-triple negative 117 881 <0.001 802 250 0.016 266 760 0.315
Triple negative 52 172 185 36 64 155
Basal phenotype
Non-basal 112 813 0.003 745 219 0.552 257 689 0.487
Basal 49 205 207 55 64 191
LVI
Negative 85 603 0.408 548 168 0.627 194 507 0.464
Positive 48 290 271 77 86 251
IT-LVI
Negative 106 786 0.014 711 216 0.609 241 666 0.410
Positive 26 107 107 29 39 91
PT-LVI
Negative 96 654 0.798 602 177 0.696 220 542 0.022
Positive 37 239 217 68 60 216
The P-values are resultant from the Pearson χ2 test of association. Signiﬁcant P-values are indicated by bold. The cohort was comprised of 1371 patients
(total clinicopathological variables shown in Table 1); however, scores were not available for every patient for each marker (calpastatin: 1266 of 1371;
calpain-1: 1315 of 1371; calpain-2: 1286 of 1371). The number of observations for each marker is shown for each clinicopathological variable; the table does
not include the number of observations where clinicopathological data were not available.
NPI, Nottingham prognostic index; ER, oestrogen receptor; PgR, progesterone receptor; LVI, lymphatic vessel invasion; IT-LVI, intra-tumoural LVI; PT-LVI,
peri-tumoural LVI.
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associated with grade, ER and PgR status and triple-negative
disease, and calpain-2 expression was associated with peri-
tumoural lymphatic vessel invasion.
The calpain system has been implicated in various aspects of
cancer progression, including migration and cell survival [13].
It functions as a cysteine protease that is responsible for the
controlled proteolysis of a number of important cellular
substrates. Both µ-calpain (calpain-1 is the large catalytic
subunit) and m-calpain (calpain-2 is the large catalytic subunit)
require calcium for their activity and are named for the calcium
concentration required for their activity in vitro [12]. There are
several mechanisms that enhance calpain activation through
reducing the concentration of calcium required, such as
interaction with membrane phospholipids and autolysis of the
protein itself. Furthermore, m-calpain can be phosphorylated
by ERK and protein kinase Cι (PKCι), which has been shown
to alter cell adhesion and migration [25, 26].
This study used a large consecutive series of invasive breast
carcinoma patients to demonstrate an association between
breast cancer-speciﬁc overall survival and calpain-2 expression
in both pragmatically deﬁned basal-like and triple-negative
phenotype subgroups. Furthermore, the importance of
calpain-2 expression was veriﬁed in a separate, deﬁned cohort
of invasive breast cancer patients. This provides strong
evidence that determining calpain-2 expression is of prognostic
signiﬁcance. Interestingly, determining calpain-2 expression
could stratify patients with basal-like and triple-negative
disease into two groups, one with a poor prognosis and one
that behaved like patients with non-basal-like or receptor-
positive disease. The pragmatic immunohistochemical
deﬁnition of basal-like breast cancers used in this study was
expression of the basal cytokeratins, CK5/6 and/or CK14.
There are a number of immunohistochemical markers that
have been used for determination of basal-like phenotype,
varying from those that include EGFR and p53 [6]. There is no
current information that would explain why calpain-2
expression is of such importance in basal-like and triple-
negative breast cancer; however, overexpression of m-calpain in
these patients could be expected to alter both cellular
migration and invasion, which would have an important
impact on patient outcome in terms of breast cancer-speciﬁc
survival.
The current study examined the expression levels of calpain-1,
calpain-2 and calpastatin, and cannot predict the subsequent
activity levels of the protease. It would be of interest to
determine calpain activity, which might be possible using
antibodies against the products of calpain proteolysis; however,
such reagents would require validation to determine their
suitability for use in malignant tissue [27, 28]. In addition, the
small regulatory subunit of both µ-calpain and m-calpain,
calpain-4 (CAPNS1) was not investigated as part of this study.
In future works, it may be of interest to determine the
expression level of calpain-4.
The expression of calpain-1, calpain-2 and calpastatin has
been previously reported in HER2-positive breast cancer
patients treated with trastuzumab following adjuvant
chemotherapy to demonstrate that calpain-1 expression is
associated with relapse-free survival [14]. Calpain-1 and
calpain-2 expression were not associated with any
clinicopathological variables and calpastatin was signiﬁcantly
associated with NPI and lymph node status; these observations
differ to the current data, but may be due to the deﬁned
HER2-positive cohort reported previously. We have previously
reported an association between low calpastatin expression and
lymphatic vessel invasion [15], which was also observed in the
current study; however, this association is limited to intra-
tumoural lymphatic vessel invasion.
Expression of the large catalytic subunit of m-calpain
(calpain-2) is signiﬁcantly associated with clinical outcome of
patients with triple-negative and pragmatically deﬁned basal-
like disease in terms of breast cancer-speciﬁc survival. As part
of future research, multi-centre, non-selected breast cancers
Figure 2. Kaplan–Meier analysis of breast cancer-speciﬁc survival showing
the impact of calpain-2 expression in the primary cohort of 1371 patients
with signiﬁcance determined using the log-rank test. The numbers shown
below the Kaplan–Meier survival curves are the number of patients at risk
at the speciﬁed month. (A) Subgroup analysis of basal-like disease where, 1:
non-basal-like disease with low calpain-2 expression (n = 206); 2: non-
basal-like disease with high capain-2 expression (n = 568); 3: basal-like
disease with low calpain-2 expression (n = 55); 4: basal-like disease with
high calpain-2 expression (n = 168). (B) Subgroup analysis of triple-negative
disease where, 1: non-triple-negative disease with low calpain-2 expression
(n = 214); 2: non-triple-negative disease with high capain-2 expression (n =
629); 3: triple-negative disease with low calpain-2 expression (n = 54); 4:
triple-negative disease with high calpain-2 expression (n = 137).
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must be investigated to test if determining calpain-2 expression
would be of clinical beneﬁt and produce recommendations for
standardisation of staining and assessment. Inhibition of the
proteolytic functions of calpain may provide a therapeutic
opportunity for certain subgroups of patients.
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